Hikal rose 19.58% to ₹240.36 on 3 September 2026, after closing at ₹201.00 in the prior session. Turnover reached about ₹4.66bn versus a 20-day average of roughly ₹211.1m, with volume of 20.2m shares, indicating an unusually active session relative to recent trading.
No direct company-specific headline, regulatory filing, or event was supplied in the context, so the move cannot be tied here to a stated catalyst. The available data only confirms the price and liquidity swing, not the reason behind it. Hikal is classified under Healthcare and the Pharmaceuticals & Biotechnology industry.